Patents by Inventor Michael Hite
Michael Hite has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240074701Abstract: What is described is wearable device for a user comprising: at least one motion-state sensor; at least one oximetry sensor; an alarm module configured for transmitting an emergency signal; and a device control logic comprising firmware or embedded software, wherein the motion-state sensor activates the device control logic upon sensing a no-motion or low-motion state of the user, and the oximetry sensor activates the device control logic during a low-oxygenation or low-respiration state of the user, in which the wearable device continuously monitors and detects a respiratory emergency of the user. Also described is a system comprising the wearable device to communicate an emergency alert to appropriate responders, and a method of using the wearable device for a person at risk of respiratory failure.Type: ApplicationFiled: April 26, 2023Publication date: March 7, 2024Inventors: Michael Hite, Desislava Hite
-
Publication number: 20240075223Abstract: A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. The inlet is disposed at the proximal end. A nozzle body is secured to the drug product inlet. Two or more channels are disposed within the body. Two or more orifice apertures are disposed at the distal end of the nozzle.Type: ApplicationFiled: November 8, 2023Publication date: March 7, 2024Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford
-
Patent number: 11890412Abstract: A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. The inlet is disposed at the proximal end. A nozzle body is secured to the drug product inlet. Two or more channels are disposed within the body. Two or more orifice apertures are disposed at the distal end of the nozzle.Type: GrantFiled: February 1, 2021Date of Patent: February 6, 2024Assignee: Impel Pharmaceuticals Inc.Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford
-
Patent number: 11730903Abstract: A compound delivery device for delivering a plume derived from a propellant and a drug formulation. The drug formulation is in an intranasal dosage form in the form of powder, suspension, dispersion or liquid. The propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing chamber where the intra-nasal dosage form is aerosolized. The aerosolized intra-nasal dosage form passes through a nozzle thus delivering a plume to the olfactory region of a user's nasal cavity.Type: GrantFiled: October 25, 2019Date of Patent: August 22, 2023Assignee: Impel Pharmaceuticals Inc.Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford, Rodney J. Y. Ho
-
Publication number: 20210322689Abstract: A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. The inlet is disposed at the proximal end. A nozzle body is secured to the drug product inlet. Two or more channels are disposed within the body. Two or more orifice apertures are disposed at the distal end of the nozzle.Type: ApplicationFiled: February 1, 2021Publication date: October 21, 2021Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford
-
Patent number: 11007332Abstract: A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. The inlet is disposed at the proximal end. A nozzle body is secured to the drug product inlet. Two or more channels are disposed within the body. Two or more orifice apertures are disposed at the distal end of the nozzle.Type: GrantFiled: December 15, 2017Date of Patent: May 18, 2021Assignee: IMPEL NEUROPHARMA, INC.Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford
-
Patent number: 10940278Abstract: A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. The inlet is disposed at the proximal end. A nozzle body is secured to the drug product inlet. Two or more channels are disposed within the body. Two or more orifice apertures are disposed at the distal end of the nozzle.Type: GrantFiled: February 6, 2018Date of Patent: March 9, 2021Assignee: IMPEL NEUROPHARMA, INC.Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford
-
Publication number: 20200078544Abstract: A compound delivery device for delivering a plume derived from a propellant and a drug formulation. The drug formulation is in an intranasal dosage form in the form of powder, suspension, dispersion or liquid. The propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing chamber where the intra-nasal dosage form is aerosolized. The aerosolized intra-nasal dosage form passes through a nozzle thus delivering a plume to the olfactory region of a user's nasal cavity.Type: ApplicationFiled: October 25, 2019Publication date: March 12, 2020Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford, Rodney J.Y. Ho
-
Patent number: 10507295Abstract: A compound delivery device for delivering a plume derived from a propellant and a drug formulation. The drug formulation is in an intranasal dosage form in the form of powder, suspension, dispersion or liquid. The propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing chamber where the intra-nasal dosage form is aerosolized. The aerosolized intra-nasal dosage form passes through a nozzle thus delivering a plume to the olfactory region of a user's nasal cavity.Type: GrantFiled: October 28, 2016Date of Patent: December 17, 2019Assignee: Impel Neuropharma, Inc.Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford, Rodney J. Y. Ho
-
Publication number: 20180236190Abstract: A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. The inlet is disposed at the proximal end. A nozzle body is secured to the drug product inlet. Two or more channels are disposed within the body. Two or more orifice apertures are disposed at the distal end of the nozzle.Type: ApplicationFiled: February 6, 2018Publication date: August 23, 2018Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford
-
Publication number: 20180153817Abstract: A composition is described having improved oral permeability of polar agents such as neuraminidase inhibitors. The composition includes one or more polar agents and one or more permeability enhancers such that the composition increases the amount of the polar agent capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 Cell membrane in the absence of the permeability enhancer. Oral dosage forms including the composition, and methods of treating or preventing influenza infection are also provided.Type: ApplicationFiled: October 6, 2017Publication date: June 7, 2018Applicant: ALA WAI PHARMA, INC.Inventors: Eric Holmes, Michael Hite
-
Publication number: 20180126101Abstract: A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. The inlet is disposed at the proximal end. A nozzle body is secured to the drug product inlet. Two or more channels are disposed within the body. Two or more orifice apertures are disposed at the distal end of the nozzle.Type: ApplicationFiled: December 15, 2017Publication date: May 10, 2018Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford
-
Patent number: 9919117Abstract: A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. The inlet is disposed at the proximal end. A nozzle body is secured to the drug product inlet. Two or more channels are disposed within the body. Two or more orifice apertures are disposed at the distal end of the nozzle.Type: GrantFiled: November 8, 2013Date of Patent: March 20, 2018Assignee: IMPEL NEUROPHARMA INC.Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford
-
Patent number: 9730895Abstract: A method for providing immediate and sustained release of ibuprofen to a subject, including administering, in a single dose, a modified release formulation of ibuprofen including a hydrophilic polymer, ibuprofen in solid dosage form uniformly dispersed in the polymer, and a dissolution additive and an inert formulation additive dispersed in the polymer. The hydrophilic polymer comprises a first hydroxypropyl methylcellulose (HPMC) having a viscosity of about 100 cps and a second HPMC having a viscosity between about 200 cps to about 50,000 cps. The solid dosage form is a monolithic tablet that demonstrates a mean ibuprofen plasma concentration in a subject greater than or equal to 6.4 ?g/ml within two hours of administration, and also demonstrates a mean ibuprofen plasma concentration in a subject greater than or equal to 6.4 ?g/ml for at least 8 hours after administration.Type: GrantFiled: February 2, 2015Date of Patent: August 15, 2017Inventors: Michael Hite, Cathy Federici, Alan Brunelle, Stephen Turner
-
Publication number: 20170157059Abstract: A composition is described having improved oral permeability of polar agents such as neuraminidase inhibitors. The composition includes one or more polar agents and one or more permeability enhancers such that the composition increases the amount of the polar agent capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 Cell membrane in the absence of the permeability enhancer. Oral dosage forms including the composition, and methods of treating or preventing influenza infection are also provided.Type: ApplicationFiled: February 24, 2017Publication date: June 8, 2017Applicant: ALA WAI PHARMA, INC.Inventors: Eric Holmes, Michael Hite
-
Patent number: 9579383Abstract: A composition is described having improved oral permeability of polar agents such as neuraminidase inhibitors. The composition includes one or more polar agents and one or more permeability enhancers such that the composition increases the amount of the polar agent capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 Cell membrane in the absence of the permeability enhancer. Oral dosage forms including the composition, and methods of treating or preventing influenza infection are also provided.Type: GrantFiled: November 11, 2013Date of Patent: February 28, 2017Assignee: ALA WAI PHARMA, INC.Inventors: Eric Holmes, Michael Hite
-
Publication number: 20170043109Abstract: A compound delivery device for delivering a plume derived from a propellant and a drug formulation. The drug formulation is in an intranasal dosage form in the form of powder, suspension, dispersion or liquid. The propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing chamber where the intra-nasal dosage form is aerosolized. The aerosolized intra-nasal dosage form passes through a nozzle thus delivering a plume to the olfactory region of a user's nasal cavity.Type: ApplicationFiled: October 28, 2016Publication date: February 16, 2017Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford, Rodney J.Y. Ho
-
Patent number: 9550036Abstract: A compound delivery device for delivering a plume derived from a propellant and a drug formulation. The drug formulation is in an intranasal dosage form in the form of powder, suspension, dispersion or liquid. The propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing chamber where the intra-nasal dosage form is aerosolized. The aerosolized intra-nasal dosage form passes through a nozzle thus delivering a plume to the olfactory region of a user's nasal cavity.Type: GrantFiled: September 3, 2013Date of Patent: January 24, 2017Assignee: Impel NeuroPharma Inc.Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford, Rodney J. Y. Ho
-
Publication number: 20150196491Abstract: A method for providing immediate and sustained release of ibuprofen to a subject, including administering, in a single dose, a modified release formulation of ibuprofen including a hydrophilic polymer, ibuprofen in solid dosage form uniformly dispersed in the polymer, and a dissolution additive and an inert formulation additive dispersed in the polymer. The hydrophilic polymer comprises a first hydroxypropyl methylcellulose (HPMC) having a viscosity of about 100 cps and a second HPMC having a viscosity between about 200 cps to about 50,000 cps. The solid dosage form is a monolithic tablet that demonstrates a mean ibuprofen plasma concentration in a subject greater than or equal to 6.4 ?g/ml within two hours of administration, and also demonstrates a mean ibuprofen plasma concentration in a subject greater than or equal to 6.4 ?g/ml for at least 8 hours after administration.Type: ApplicationFiled: February 2, 2015Publication date: July 16, 2015Inventors: Michael HITE, Cathy FEDERICI, Alan BRUNELLE, Stephen TURNER
-
Patent number: 9028869Abstract: The present invention is a solid dosage form for oral administration of ibuprofen comprising a modified release formulation of ibuprofen which provides an immediate burst effect and thereafter a sustained release of sufficient ibuprofen to maintain blood levels at least 6.4 ?g/ml over an extended period of at least 8 hours following administering of a single dose.Type: GrantFiled: February 16, 2010Date of Patent: May 12, 2015Assignee: Shasun Pharmaceuticals LimitedInventors: Michael Hite, Cathy Federici, Alan Brunelle, Stephen Turner